Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update

Got To Article
Opiant to use Aptar Pharma’s Unit Dose System - Upcoming FDA meeting in December to review Pharmacodynamic study in healthy volunteers and 505 (b) (2) submission strategy - Opiant continues to expect to file a New Drug Application by end of 2021 - The Centers for Disease Control and Prevention reports an increase in fatal drug overdoses in the first three months of 2020 putting the U.
0 comments

Clearlake Capital-Backed symplr Names Software Industry Veteran BJ Schaknowski As CEO

Got To Article
HOUSTON and SANTA MONICA, Calif., Nov. 13, 2020 /PRNewswire/ -- symplr, the leading global healthcare governance, risk management, and compliance ("GRC") software-as-a-service ("SaaS") platform, backed by Clearlake Capital Group, L.P. (together with its ...
0 comments